Differential Expression of Phosphorylated NF-κB/RelA in Normal and Psoriatic Epidermis and Downregul...
Differential Expression of Phosphorylated NF-κB/RelA in Normal and Psoriatic Epidermis and Downregulation of NF-κB in Response to Treatment with Etanercept
About this item
Full title
Author / Creator
Publisher
Danvers, MA: Elsevier Inc
Journal title
Language
English
Formats
Publication information
Publisher
Danvers, MA: Elsevier Inc
Subjects
More information
Scope and Contents
Contents
Etanercept, a recombinant human tumor necrosis factor (TNF) receptor fusion protein, is FDA approved for psoriasis and psoriatic arthritis. TNFα increases the synthesis of proinflammatory cytokines and leads to the activation of multiple signaling pathways, including nuclear factor kappa B (NF-κB). The Rel/NF-κB transcription factors play a central...
Alternative Titles
Full title
Differential Expression of Phosphorylated NF-κB/RelA in Normal and Psoriatic Epidermis and Downregulation of NF-κB in Response to Treatment with Etanercept
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_journals_210362675
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_210362675
Other Identifiers
ISSN
0022-202X
E-ISSN
1523-1747
DOI
10.1111/j.0022-202X.2005.23735.x
